key: cord-0704151-w751g4lu
authors: Hammad, Tarek A.; Parikh, Melanie; Tashtish, Nour; Lowry, Cynthia M.; Gorbey, Diane; Forouzandeh, Farshad; Filby, Steven J.; Wolf, William M.; Costa, Marco A.; Simon, Daniel I.; Shishehbor, Mehdi H.
title: Impact of COVID‐19 pandemic on ST‐elevation myocardial infarction in a non‐COVID‐19 epicenter
date: 2020-06-01
journal: Catheter Cardiovasc Interv
DOI: 10.1002/ccd.28997
sha: ffbc4a63b2ba0734387fde4a87908d8653219f89
doc_id: 704151
cord_uid: w751g4lu

OBJECTIVES: We sought to study the impact of COVID‐19 pandemic on the presentation delay, severity, patterns of care, and reasons for delay among patients with ST‐elevation myocardial infarction (STEMI) in a non‐hot‐spot region. BACKGROUND: COVID‐19 pandemic has significantly reduced the activations for STEMI in epicenters like Spain. METHODS: From January 1, 2020, to April 15, 2020, 143 STEMIs were identified across our integrated 18‐hospital system. Pre‐ and post‐COVID‐19 cohorts were based on March 23rd, 2020, whenstay‐at‐home orders were initiated in Ohio. We used presenting heart rate, blood pressure, troponin, new Q‐wave, and left ventricle ejection fraction (LVEF) to assess severity. Duration of intensive care unit stay, total length of stay, door‐to‐balloon (D2B) time, and radial versus femoral access were used to assess patterns of care. RESULTS: Post‐COVID‐19 presentation was associated with a lower admission LVEF (45 vs. 50%, p = .015), new Q‐wave, and higher initial troponin; however, these did not reach statistical significance. Among post‐COVID‐19 patients, those with >12‐hr delay in presentation 31(%) had a longer average D2B time (88 vs. 53 min, p = .033) and higher peak troponin (58 vs. 8.5 ng/ml, p = .03). Of these, 27% avoided the hospital due to fear of COVID‐19, 18% believed symptoms were COVID‐19 related, and 9% did not want to burden the hospital during the pandemic. CONCLUSIONS: COVID‐19 has remarkably affected STEMI presentation and care. Patients' fear and confusion about symptoms are integral parts of this emerging public health crisis.

Contrary to the anticipated surge in myocardial infarction (MI) related to the novel coronavirus, 1 there have been reports that the COVID-19 pandemic has significantly reduced the number of activations for STelevation myocardial infarction (STEMI) in a majority of cities with devastating spread of COVID-19 cases. 2 The mechanism of this decline is unclear. Furthermore, little work has been done to investigate the impact of this pandemic on STEMI in regions, like Northeast Ohio, where numbers of total cases and overall fatality are relatively lower. We sought to examine STEMI presentation delay, severity, and patterns of care before and after the COVID-19 pandemic in a non-hot-spot region. Additionally, we examined specific reasons for the delay in symptom onset to presentation among the post-COVID-19 cohort.

From January 1, 2020, to April 15, 2020, a total of 143 STEMI subjects were identified across our 18-hospital system in a non-hot-spot region for COVID-19. Of these, 10 hospitals perform cardiac catheterization, 3 do not perform primary percutaneous coronary intervention (PPCI), 5 have level I cardiac catheterization laboratories that offer both PPCI and open-heart surgery, and 2 are level II that only offer PPCI.

All study subjects had a combination of ischemic myocardial symptoms and electrocardiographic ST elevation, or its equivalent, in addition to elevated cardiac troponin on initial or subsequent testing.

Each patient with STEMI, except one who declined escalation of care, underwent emergent PPCI. Patients were divided into pre-and post-COVID-19 cohorts based on March 23, 2020, when stay-at-home orders and cancellations of non-essential procedures were initiated in Ohio. The study was approved by the Institutional Review Board.

Data were deidentified, and informed consent was waived for all study participants.

We hypothesized that due to fear of contracting COVID-19 or confusion about symptoms, patients with STEMI on or after March 23, 2020, would likely present with longer delays from the onset of symptoms leading to worsened health status at the time of presentation. We used presenting heart rate, blood pressure (BP), troponin, the presence of new Q-wave on the earliest electrocardiogram, and initial left ventricle ejection fraction (LVEF) to assess the presentation severity between the pre-and post-COVID-19 cohorts. Duration of intensive care unit (ICU) stay, total length of stay, door-to-balloon (D2B) time, and radial versus femoral approach were used to compare patterns of care between these two time periods. All data were collected prospectively and independently by certified chest pain coordinators as part of the National Cardiovascular Data Registry, and were supplemented by detailed retrospective review of all angiograms, electrocardiograms, echocardiograms, laboratory results, and hospital and emergency medical services records. Reasons for delay in presentation for patients in the post-COVID-19 cohort were confirmed with telephone calls.

Baseline characteristics and important procedural characteristics, if continuous variables, were compared using t-test (if parametric variables) or Wilcoxon rank sum test (if nonparametric variables). Categorical variables were presented as percentages and were compared using chi-square test, unless the frequency was <5, and then Fisher exact test was utilized. Differences in STEMI presentation severity and care pattern metrics between the two groups were examined in the same manner. In addition, presentation severity measures (incidence of late presentation, percentage of new Q-waves, and average initial troponin and LVEF) were compared between the two cohorts using different cutoffs to define late presentation (>12, >24, >48, and >72 hr). We also examined reasons for delay among late presenting patients with STEMI in the post-COVID-19 period. These were divided into four categories; avoidance of the emergency department (ED) due to fear of COVID-19; belief that the symptoms were COVID-19 related; desire not to burden the ED given the COVID-19 pandemic; and reasons that were not COVID-19 related.

In order to examine internal delays due to concerns about COVID-19, D2B times were compared between the pre-and post-COVID-19 cohorts and between those who presented with greater and less than a 12-hr delay in each cohort. All comparisons were two-sided and statistical significance was determined as p < .05. All analyses were performed using the R statistical software, version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). were seen as shown in Table 1 . Table 2) . Subgroup analysis using different cutoffs to define late presentation (>12, >24, >48, and >72 hr after symptom onset)

found that delayed patients in the post-COVID-19 cohort also trended toward more severe presentations compared to those in the pre-COVID-19 cohort regardless of which cutoff was used (Figure 1) .

Baseline characteristics of patients with ST-elevation myocardial infarction pre-and post-COVID-19 

Of the 35 patients with STEMI in the post-COVID-19 group, 11 presented greater than 12 hr after symptoms onset. Of these, 27% avoided the ED due to fear of COVID-19, 18% believed symptoms were COVID-19 related, and 9% did not want to burden the ED given the COVID-19 pandemic (Table S1 ). The clinical courses of these 11 patients are depicted in Figure 2 . 

In the studied hospital system, we maintained PPCI for all STEMI patients and did not experience a surge, yet we uncovered untoward consequences of COVID-19. We found that patients in the post-COVID-19

period were more likely to present late and have lower LVEF, higher initial and peak troponin, and new Q-waves on presentation. More importantly, half of the patients did not seek timely medical help due to COVID- Unfortunately, it appears that public trust in the safety of the health care system has been eroded and this needs to be addressed to prevent further adverse outcomes. 6 While the prehospital phase of ischemic duration in STEMI is strongly associated with patient outcomes, 7-9 the in-hospital phase D2B time is also critically important. 10 metric with strong evidence on its impact on mortality. 12 When comparing D2B times in those with <12 hr vs. >12 hr from symptom onset to presentation in the post-COVID-19 period, there was a significant increase in D2B of 33 min for those who already had prolonged prehospital ischemic time (double jeopardy). Further investigation revealed that 40% of those internal delays were related to COVID-19. 

Our study has several limitations, especially short-term follow-up.

However, our results most likely underestimate the impact of COVID-19 on the long-term outcomes of STEMI care. Importantly, these data were collected from a region with low COVID-19 prevalence and may F I G U R E 3 Door-to-balloon (D2B) times and peak troponin levels with and without presentation delay in the pre-and-post-COVID-19 cohorts. D2B times and peak troponin levels were not different between the pre-and post-COVID-19 cohorts. However, when comparing patients with and without >12-hr presentation delay within these two cohorts, we found that (b) the D2B times and (d) peak troponin levels were significantly higher in the patients who presented greater than 12 hr after symptom onset in the post-COVID-19 cohort [Color figure can be viewed at wileyonlinelibrary.com] demonstrate trends difference from areas like New York or other epicenters for COVID-19, although this impact may be larger in COVID-19 epicenters. 17 Lastly, our sample size is small, but represents a large system with 18 hospitals, 7 of which offer PPCI and cover a large geographic region in Northeast Ohio.

The current evidence suggests a developing public health crisis within a pandemic. Studies are indicating that patients with acute and chronic conditions suffer major consequences due to multiple factors related to COVID-19. Some of these, such as unavailability of beds and overloaded EDs in New York or other epicenters, are not easy to address; however, public fears and confusion regarding symptomatology are modifiable. We encourage public health officials, members of the media, and local physician communities to address our patients' fear, provide easily accessible professional opinion through virtual EDs and telemedicine, and once again gain the trust of our patients.

ST-segment elevation in patients with Covid-19-a case series

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes

Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score

Management of Acute Myocardial Infarction during the COVID-19 pandemic

The untold toll-the pandemic's effects on patients without Covid-19

Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care

Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for st-segment elevation myocardial infarction

Relationship of symptomonset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

Shorter door to balloon time, better long term clinical outcomes in St-segment elevation myocardial infarction patients Japanese registry of acute myocardial infarction diagnosed by universal definition substudy

Door-to-balloon time correlates better with patients outcomes than symptom-to-balloon time

ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines

Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial

Safety and feasibility of early hospital discharge in STsegment elevation myocardial infarction-a prospective and randomized trial in low-risk primary percutaneous coronary intervention patients (the Safe-Depart Trial)

Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry

Virtually perfect? telemedicine for Covid-19

STEMI care during COVID-19: losing sight of the forest for the trees

Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a non-COVID-19 epicenter

The authors are grateful to all nurses, technicians, chest pain coordinators, and physicians for their selfless efforts to care for these patients.

The authors declare no potential conflict of interest.

https://orcid.org/0000-0002-4888-2431